Introduction
Genetic reprograming of T cells to express a chimeric antigen receptor (CAR) offers a novel approach for treating hematologic malignancies. [1] [2] [3] T cells transduced with an anti-CD19 CAR composed of CD28 and CD3ζ signaling domains produce interferon-γ (IFN-γ) in a CD19-specific manner, kill primary leukemia cells, and undergo CD19-target dependent proliferation. 4 Treatment of B-cell malignancies with anti-CD19 CAR T cells results in durable remissions in a significant number of patients. This treatment is associated with B-cell aplasia due to endogenous CD19 expression on B cells. Additionally, treatment with anti-CD19 CAR T celltherapy can cause cytokine release syndrome (CRS) and neurologic toxicity (NT). Anti-CD19
CAR T cell-therapy has not yet been fully characterized mechanistically. 5, 6 An optimized, lowdose conditioning chemotherapy regimen of cyclophosphamide and fludarabine has been shown to enhance engraftment of CAR T cells through lymphodepletion and by increasing serum cytokine levels, most notably interleukin (IL)-15. 6 Levels of IL-15 are correlated with CAR T-cell expansion, which in turn correlated with clinical response and toxicities. 6 This study also
showed that greater expansion of CAR T cells in blood and higher serum levels of IL-15, granzyme B, and IL-10 were associated with grade 3 or higher NT. 6 T cells deploy a broad spectrum of immune programs, 7 and it is unclear which specifically influence in vivo expansion and activity of CAR T cells. We hypothesized that CAR T cells orchestrate clinical activity by deploying multiple immune programs that functionally complement each other. To address this hypothesis, we evaluated CAR T-cell product functionality using a high-content single-cell multiplex cytokine analysis 8,9 that allowed for identification of a subset of polyfunctional T cells in CAR T-cell products that produce 2 or more cytokines upon stimulation with CD19 antigen in vitro. We also examined associations of a prespecified polyfunctionality strength index (PSI) applied to CAR T-cell products, CAR T-cell expansion in vivo, objective
For personal use only. on August 14, 2018. by guest www.bloodjournal.org From response (OR), and toxicities. We show that highly polyfunctional T cells within CAR T-cell products are significantly associated with clinical response and that a subset of polyfunctional CD4+ T cells producing IL-17A is associated with grade 3 or higher NT.
Methods

Patient demographics and treatment protocol
The study (NCT00924326) cohort comprised 22 patients with recently described clinical outcomes. 6 Of 22 treated patients, 19 had diffuse large B-cell lymphoma (DLBCL), 2 had follicular lymphoma, and 1 had mantle cell lymphoma (Table 1) . Of 19 patients with DLBCL, 11
had chemotherapy-refractory lymphoma. Five patients with DLBCL had lymphoma that relapsed 10 months or less after autologous stem cell transplant as their last treatment before protocol enrollment. Eleven patients with DLBCL were high risk, according to the second-line, ageadjusted International Prognostic Index. 10 The median number of unique lymphoma therapies received before protocol enrollment was 4 (range, 1-7). Products from 20 patients were evaluable by single-cell multiplex cytokine profiling and used in this exploratory study (Table 1) .
Objective response (OR) is defined as partial (PR) or complete (CR) defined by Cheson 2014
criteria. 27 Stable (SD) and progressive disease (PD) correspond to lack of objective response (non-responders). CRS and NT were graded as previously reported. 
T-cell polyfunctionality evaluation by single-cell cytokine profiling and calculation of PSI
Cryopreserved CAR T-cell products comprising about 40%-60% CAR+ T cells, measured by surface expression of the scFv by flow cytometry, were thawed and cultured in complete Cell Therapy Systems (CTS) (Thermo Fisher Cell Therapy Systems, Waltham, MA) medium with IL-2 (10 ng/mL, Biolegend, San Diego, CA) at a density of 1 × 10 6 /mL in a 37°C, 5%
For personal use only. on August 14, 2018. by guest www.bloodjournal.org From CO 2 incubator. After overnight recovery, viable T cells were enriched using Ficoll-Paque Plus medium (Fisher Scientific, Pittsburgh, PA). CD4+/CD8+ T-cell subsets were separated using anti-CD4 or anti-CD8 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and stimulated with K562 cells transduced with either CD19 or nerve growth factor receptor (NGFR) at a ratio of 1:2 for 20 hours at 37°C, 5% CO 2 . The co-cultured CD4+ or CD8+ T cells were further enriched using anti-CD19 or anti-NGFR-conjugated magnetic beads to deplete CD19-K562 or NGFR-K562 cells. Presence of CD4+ or CD8+ CAR T cells was confirmed by staining with Alexa Fluor 647 (Thermo Fisher Cell Therapy Systems, Waltham, MA) conjugated anti-CD4 or anti-CD8 antibody at room temperature for 10 minutes, rinsed once with phosphate-buffered saline, and resuspended in complete CTS medium at a density of 1 × 10 6 /mL. Approximately 30 µL of the cell suspension was loaded into the single-cell barcode chip (SCBC) microchip 9 for single-cell secretomics evaluation.
For each sample, a 32-plex assay measured secreted proteins from ∼2000 T cells ( Figure 1 ).
Raw microscopy and microarray scans of the cell samples (loaded onto the SCBC) and protein secretion data were analyzed using proprietary image processing software to determine the locations of chambers containing single cells and subsequent extraction of their secretion readouts. Data from empty cell chambers were used to measure background intensity levels for each analyzed protein. Single-cell readouts were then normalized using the background readouts to determine significant secretions and compare profiles across assays. Proprietary software and the R statistical package (R Foundation for Statistical Computing, Vienna, Austria)
were used for statistical data analysis and visualizations.
A single cell functional profile was determined for each evaluable product. Profiles were categorized into effector (Granzyme B, IFN-γ, MIP-1α, Perforin, TNF-α, TNF-β), stimulatory (GM-CSF, IL-2, IL-5, IL-7, IL-8, IL-9, IL-12, IL-15, IL-21), regulatory (IL-4, IL-10, IL-13, IL-22,   TGF-β1, sCD137, sCD40L), chemoattractive (CCL-11, IP-10, MIP-1β, RANTES), and   inflammatory (IL-1b, IL-6, IL-17A, IL-17F, 
The CD4+ and CD8+ PSIs were computed for corresponding CD19-K562 or NGFR-K562 stimulated samples from each donor. An overall PSI, (the average of CD4+ and CD8+ PSI), was also computed. Any notable statistically significant associations between preinfusion single-cell CAR T data and clinical outcome were determined, cognizant of the clinical outcome of these patients (OR, CRS, and NT). More specifically, associations between overall PSI, CD4+ PSI, CD8+ PSI, IL-17A CD4+ PSI, and clinical outcomes were determined. Mann-Whitney U tests were used to determine P values of these associations. Any associations between single-cell metrics (eg, PSI) and other pre-and postinfusion metrics described throughout this paper (eg, in vivo CAR T-cell expansion, IL-15 day 0 patient levels, co-culture and serum cytokine levels, T-cell phenotype frequencies) were determined by measuring the Spearman correlation between these metrics.
In some cases, 2 metrics were combined into a joint metric to test their association with patient outcome. The metrics were added to each other after each was first standardized to have unit variance. This standardization was achieved by dividing the metrics by their respective standard deviation to bring them to a common magnitude/scale. Thus, when added to one other, the metrics carry a similar weight and one does not "overpower" the other. 
Evaluation of percentage of T17 and Treg cells by epigenetic analysis
Epigenetic analysis was performed based on previously characterized methods, 11 at Epiontis GmbH (Berlin, Germany). Genomic DNA was isolated using the DNeasy tissue kit (Qiagen)
following the protocol for cultured animal cells. Bisulfite treatment of genomic DNA was performed. A PCR was performed in a final volume of 25 µL containing 1× PCR buffer, 1 U Taq DNA polymerase (Qiagen), 200 µmol/L dNTP, 12.5 pmol each of forward and reverse primers, and 7 ng bisulfite-treated genomic DNA at 95°C for 15 minutes, and 40 cycles of 95°C for 1 minute, 55°C for 45 seconds and 72°C for 1 minute, and a final extension step of 10 minutes at 72°C. The PCR products were purified using ExoSAP-IT (USB Corp, Cleveland, OH) and sequenced by applying the PCR primers and the ABI Big Dye Terminator v1.1-chemistry (Applied Biosystems) followed by capillary electrophoresis on an ABI 3100 genetic analyzer; ESME was used to interpret AB1 files.
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Determination of product T-cell phenotypes by flow cytometry
For CD4, CD8, and central memory phenotype determination, we utilized a method similar to one described previously. 5 CAR+ CD3+ events were gated and the percentage of cells expressing memory markers CCR7 and CD45RA was determined. Appropriate isotype control antibodies were used in all experiments. The memory antibodies used were anti-CD45RA
(eBioscience, San Diego, CA clone HI100) and anti-CCR7 (R&D Systems clone 150503).
Gene expression analysis
Gene expression analysis was performed at NanoString Technologies (Seattle, WA).
Cryopreserved cells were thawed and enumerated using a Vi-CELL automated cell counter 
Combined indexes of product PSI and CAR T cell expansion or pre-CAR T cell-infusion levels of IL-15 correlated strongly with clinical response and toxicities
After infusion, CAR T cells rapidly expand, with peak levels occurring within the first 7 to 14 days. CAR T-cell expansion, measured as peak and cumulative levels during the first month after infusion, is associated with OR and grade 3+ NT, but not grade 3+ CRS.
6
Because both CAR T-cell expansion in vivo and product PSI individually correlated with OR, we tested the impact of a composite index integrating PSI and CAR T-cell expansion on the correlation with OR. This index was computed by adding the 2 metrics to each other, after first standardizing them to have comparable variances (see Methods). This composite index combining PSI and CAR T-cell expansion improved the association with OR (P = .0046, not adjusted for multiplicity) compared to each covariate alone ( Figure 5 ). Furthermore, OR associated with CD4+ PSI plus CAR peak levels (P = .0023), but only marginally with CD8+ PSI plus CAR peak levels, respectively (P = .0507; supplemental Figure 2 ). There was no apparent association between CAR peak levels and PSI (supplemental Figure 3) . These results suggest that PSI in conjunction with CAR T-cell expansion may associate with clinical outcome to CAR T-cell therapy.
Because PSI was not significantly associated with commonly assessed product phenotypes based on CCR7 and CD45RA expression (Figure 3) , we sought to identify other potential product characteristics associated with PSI. We hypothesized that the anti-CD19 CAR construct enabled the polyfunctionality of product T cells. Therefore, CAR gene expression levels were
For personal use only. on August 14, 2018. by guest www.bloodjournal.org From measured by NanoString (Seattle, WA) in bulk product together with T-cell housekeeping molecules. Global PSI was associated with the ratio between CAR mRNA copies and T-cellspecific markers (supplemental Table 1 ). This finding suggests that product CAR expression level influences product T-cell polyfunctionality.
In contrast to PSI alone, combining product PSI or CD4+ PSI with CAR peak levels, respectively, was significantly associated with grade 3+ NT (supplemental Figure 4A) . As specified in Methods, CD4+ and CD8+ PSIs were calculated for each product by applying the same prespecified formula to the 2-product T-cell subsets separately. Based on these findings and the putative pathogenic role of Th17 cells, 12,13 we asked whether subsets of polyfunctional T cells producing cytokines including IL-17A were associated with grade 3+ NT. Cytokine-specific PSI was computed by multiplying the percentage of polyfunctional T cells secreting a given cytokine with the average signal intensity for that cytokine. These cytokine PSI values were analyzed in relation to outcome. Interestingly, IL-17A PSI, defined post hoc, plus CAR peak cell levels, had a significant association with grade 3+ NT (P =.0007; supplemental Figure 4A ).
Individually, CAR peak cell levels and IL-17A PSI were associated with grade 3+ NT (P = .0015
and P = .0574, respectively). To strengthen these findings, we explored other product attributes that may relate to IL-17A PSI. As expected, IL-17A PSI correlated strongly with the percentage of Th17 cells measured by epigenetic marking and IL-17A production in product co-culture (P < .0001 for both comparisons), and associated with the CD4/CD8 ratio, percentage of T helper (Th) cells, and IL-6 levels in product co-culture (supplemental Table 2 ). In turn, grade 3+ CRS was associated with the global product PSI plus CAR peak levels (supplemental Figure 4B ).
Because IL-15 levels initially elevated by conditioning chemotherapy were associated with CAR T-cell expansion and OR, 6 we investigated whether pre-CAR T-cell infusion levels of IL-15, in combination with PSI, were associated with clinical outcome. Indeed, product PSI combined 1 3
with IL-15 levels at day 0 had a statistically significant association with OR (P = .0033).
Objective response also was associated with PSI (P = .0119) and IL-15 (P = .0153) individually population is consistent with a CAR product containing a CD28 co-stimulatory domain, which is known to play a signaling role in both subsets. 4 Strikingly, only 20%-25% of all product cells were polyfunctional upon stimulation with CD19-expressing target cells.
The major finding of this study is that clinical response and toxicities resulting from CAR T-cell treatment were associated with the PSI of whole product, or defined T-cell subpopulations, computed utilizing a prespecified algorithm. Patient 20 is a notable outlier as the patient had a high product PSI but failed to achieve an objective response (Figure 2A ). In this patient, CAR T cells did not expand well. We hypothesize multiple possible reasons, including limited T cell proliferative capability and/or an immune exclusionary tumor environment.
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Combined indices of PSI with either peak CAR T-cell levels in blood, or with day 0 IL-15 serum levels, had more significant associations with clinical outcomes versus either parameter alone.
Day 0 IL-15 serum levels, elevated by conditioning chemotherapy, 6 were measured just before CAR T-cell infusion. Although the number of evaluable patients in this cohort was limited, OR was associated with both CD4+ PSI plus day 0 IL-15, as well as IL-17A PSI plus day 0 IL-15. IL-17A PSI was determined utilizing a formula-specified post hoc analysis to address the hypothesis that an IL-17A-producing T-cell subset may preferentially associate with outcomes.
CD4+ T cells producing IL-17A and IFN-γ can be potent Th cells with the capability to reprogram
the tumor microenvironment and enable robust, effective immune-mediated responses. 14 In addition, IL-8 and MIP-1α, co-produced by these polyfunctional Th cells, are well-known chemokines for a wide range of immune cells, including lymphocytes and myeloid cells.
14-16
Although the results point to specialized polyfunctional CD4+ T cells correlating with clinical response to a greater degree than CD8+ T cells, they do not exclude a role for effector CD8+ T cells, consistent with reports of CD8+ T cell effectiveness in metastatic melanoma.
17
Grade 3+ NT had the most statistically significant association with IL-17A PSI plus peak CAR levels in blood, suggesting the participation of specialized T cells. Grade 3+ CRS correlated with whole product PSI plus either CAR peak levels or day 0 serum IL-15 levels. These findings point to mechanisms underlying serious adverse events (AEs). The best correlates of grade 3+ NT were peak CAR levels in blood and an index combining peak CAR levels in blood plus IL-17A
PSI. These results raise the possibility that high numbers of IL-17A-producing polyfunctional CAR T (Th17) cells in vivo could be implicated in the pathogenesis of serious NT, while also 1 6
contributing to OR. Previous evidence implicated IL-17A in the pathogenesis of neuroinflammation 12,13 and participation in antitumor activity. 18 Although global product PSI was not associated with major T-cell phenotypic markers, it was associated with the level of CAR gene expression in product T cells.
Polyfunctional T cells have not been extensively evaluated in the context of engineered T-cell
therapies, but they were previously analyzed in vaccines and infectious diseases, where their presence was associated with increased protective immunity. Statistical values were computed using the Mann Whitney U test (P values were not adjusted for multiplicity). 
